Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Chidamide With AZA in MRD Positive AML After Transplant
Sponsor: Guangdong Provincial People's Hospital
Summary
acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-10-26
Completion Date
2026-12
Last Updated
2023-10-27
Healthy Volunteers
No
Conditions
Interventions
chidamide and azacitidine
chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally. azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally.
Locations (1)
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China